Childhood mortality in a cohort treated with mass azithromycin for trachoma.
about
Differential Effects of Azithromycin, Doxycycline, and Cotrimoxazole in Ingested Blood on the Vectorial Capacity of Malaria MosquitoesTrachoma and Ocular Chlamydial Infection in the Era of GenomicsTrachoma: an update on prevention, diagnosis, and treatmentWill the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutionsNon-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factorsEpidemiology and Impact of Campylobacter Infection in Children in 8 Low-Resource Settings: Results From the MAL-ED Study."Barriers" to child development and human potential: the case for including the "neglected enteric protozoa" (NEP) and other enteropathy-associated pathogens in the NTDs.Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia.Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial.A meta-analysis of the proportion of antimicrobial resistant human Salmonella isolates in Ethiopia.Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.Where the road ends, yaws begins? The cost-effectiveness of eradication versus more roadsAnthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control.Antibiotics in ingested human blood affect the mosquito microbiota and capacity to transmit malaria.Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia.Collateral benefits arising from mass administration of azithromycin in the control of active trachoma in resource limited settingsImproving our forecasts for trachoma elimination: What else do we need to know?Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in NigerAntibiotic use as a tragedy of the commons: a cross-sectional survey.Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin.Antibiotic resistance as collateral damage: the tragedy of the commons in a two-disease setting.Thinking deeper about important mass treatment trials.Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children: a protocol for a randomised, double-blind, placebo-controlled trial (the Toto Bora trial).The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management.Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi.Coverage of azithromycin mass treatment for trachoma elimination in Northwestern Ethiopia: a community based cross-sectional study
P2860
Q26315272-6CD7D25E-09D2-4116-A38C-BA6FA385E501Q26783635-D45B5ACC-8457-4AB5-A8C7-9706F2676924Q26825233-D748E707-9D64-485E-9D3F-4AF90286C2A4Q26996622-A6439761-7970-435C-B0D5-1CC5E129D24FQ28542612-1927E51F-5898-4E4C-BBD7-D9DF88E175B6Q30276167-59AF57DA-8D29-4A92-ABAB-826E3CAC086BQ30419953-3B6CFAA9-7906-4D0A-8E80-7D436FBFB154Q33588501-814D7D16-EF68-48B0-8543-B0A74DB1B2D1Q33678681-F192360B-7888-4D90-B53D-076AC65D5590Q34002736-402F07D0-850B-40D2-B693-B3F5E0E21294Q34165923-80CA8992-3720-4707-BC42-4F218BDA0A3DQ34182625-E7402B8E-F75C-4233-8D27-25C49F83DCFBQ34229701-FB6F9D3B-3B06-4B52-8B67-D1E46978B7D6Q34256756-11BDEF64-EF9C-4C51-AB61-D3526D749464Q34611086-71EA7F81-B0F3-4AC3-A614-ABF37C6F09BEQ35114250-C8FA58D8-F52E-4B2E-8EFD-FF3F6B524A0FQ35186850-FCF84139-0440-44D9-969C-BE4743703684Q35241395-77A3D535-C55E-4205-91D5-C367C5BBCC4CQ36275318-84A6AA2A-AD2C-4473-A810-DBD82CADF823Q36325816-AFC1523B-CCF6-492D-B8B5-252F14637998Q36436259-E5D0E63E-3A0F-4F9A-94B5-16A5662079EFQ36522988-6F7184D4-5474-4B44-B576-06DE165AF5E1Q37576909-10E5F494-67D0-42C0-87B9-95FEFECFE181Q38804355-94A04042-BF01-4C14-AE1F-C46ECC31DC8BQ40068835-A7F5FBB7-F12A-49A6-B8A7-88244ED21433Q43231721-8BB6F032-753A-4C48-ACA4-A05C7592EF43Q47182935-4EFE9377-E151-484E-9158-08F7D5D48C00Q47712166-B3CAA875-3222-4052-A05B-EFFAACE6DA77Q53689456-7209AE8F-976F-4935-A7C6-877969CE0265Q55431050-A5B85993-AB87-4D7E-9875-4596820774F2Q58798816-03E0C361-C73E-45A4-9108-BFC1F8C61AC5
P2860
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@ast
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@en
type
label
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@ast
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@en
prefLabel
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@ast
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@en
P2093
P2860
P50
P356
P1476
Childhood mortality in a cohort treated with mass azithromycin for trachoma.
@en
P2093
Berhan Ayele
Mulat Zerihun
Teshome Gebre
P2860
P304
P356
10.1093/CID/CIR069
P407
P50
P577
2011-04-01T00:00:00Z